Perrigo's Evidence For Nasal Spray Claims Not Enough For ASA
Ad claims that Perrigo’s BecoCleanse could protect against viruses to help prevent the occurrence of cold symptoms were not supported by sufficient evidence, the UK’s Advertising Standards Authority has ruled.
You may also be interested in...
The EU's medical device regulators have joined forces to remind consumer health firms of the rules which must be followed when marketing a nasal spray offering protection from viruses, such as influenza and SARS-CoV-2.
CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.
Xlear founder Nate Jones says FTC doesn’t argue that results and other information in research linked in social media posts, its website and a press release are false, but wants to prohibit providing information to consumers on research about preventing and treating COVID-19.